



## Anti-pneumococcal vaccination in patients with COPD in a Primay Care Health Unit

Vera Araújo<sup>1</sup>, Ana Sofia Vieira Barbosa<sup>2</sup>
<sup>1</sup>University of Minho, School of Medidicine; USF Lethes, <sup>2</sup>USF Lethes

**Aim:** The aims of this study were to know the prescription profile of anti-pneumococcal vaccines and the compliance to this vaccination by patients with Chronic Obstructive Pulmonary Disease (COPD) in a Primary Care Health Unit (PCHU).

**Method:** We conducted a retrospective, observational descriptive study in a population of patients with COPD belonging to PCHU Lethes (Ponte de Lima, Portugal). Were included all patients diagnosed with COPD and a registry of at least one spirometry . The data were obtained by consulting digital clinical process in software SClinico ® and National Health Data Platform®; were considered records until 31/07/2017.

**Results:** This study included 136 patients. A dose of two available anti-pneumococcal vaccines was prescribed in 44% of these. However, only 38% had records of at least one dose of one of the two anti-pneumococcal vaccines (what corresponds to 86% of all prescribed vaccines), and 11% had records of administration of the two vaccines. Comparing the two vaccines, 39% of patients had at least one prescription of 23-valent polysaccharide vaccine (23-PPV), of which 87% did the vaccination. It corresponds to a coverage with 23-PPV in 34% of patients with COPD. In case of 13-valent conjugate vaccine (13-PCV), 18% of patients had one prescription and, of these, 87,5% did the vaccination. Thus, the coverage with 13-PCV was 15% of patients with COPD.

**Conclusion:** This study revealed a low rate of prescription and a low rate of coverage with anti-pneumococcal vaccines in COPD patients. Given the importance of this vaccination in these patients, this study gave rise to a project of continuous quality improvement in Health Unit. These data are also a potential starting point for a study of the factors that determine the prescription of these vaccines and compliance by patients.

**Declaration of Interest:** The authors declare that they have no competing interests.

The Ethics Comittee of Local Health Unit of Alto Minho assessed and approved the research protocol.

**References and Clinical Trial Registry Information:** Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2017. [online]

Grupo de Doenças Respiratórias em Medicina Geral e Familiar (GRESP). Recommendations in antipneumococcal vaccination. [online]

Direção Geral da Saúde. Norma de Orientação Clínica 11/2015 de 23/06/2015, atualizada em 06/11/2017. [online]